Lakewood-Amedex is a Sarasota, Fla.-based biopharmaceutical company developing novel anti-infective pharmaceuticals. Its lead product, Nu-3, is a first-in-class antimicrobial expected to enter the clinic in the second half of 2014. The company is advancing a broad-spectrum Bisphosphocin™ class of antimicrobials toward human clinical trials and is developing orally available 'gene silencing' nRNA therapeutics for viral, oncology, inflammatory and other chronic indications. It plans to use the funds from the financing to advance Bisphosphocin into human trials and to increase business development, including seeking collaborations and partnerships to advance its nRNA therapeutics. The company says its products and technology are covered by an extensive patent portfolio of 74 issued and 13 pending patents. Led by President and CEO Steve Parkinson, Lakewood-Amedex focuses on treating serious infectious diseases and reducing threats from antibiotic-resistant strains such as MRSA, VRE, NDM-1 and biofilm strains.

Total raised

$6M

Funding rounds

1

Latest round

Series C

Latest activity

Jun 2014